CompletedPhase 2NCT03172598

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Studying OBSOLETE: Acquired metabolic neuropathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tanabe Pharma Corporation
Principal Investigator
General Manager
Tanabe Pharma Europe Ltd
Intervention
MT-8554 low dose(drug)
Enrollment
61 enrolled
Eligibility
18 years · All sexes
Timeline
20172018

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03172598 on ClinicalTrials.gov

Other trials for OBSOLETE: Acquired metabolic neuropathy

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Acquired metabolic neuropathy

← Back to all trials